5-10-06

MAY 0 8 2006 W Customer No.: 07278

1 FW 1614

Docket No. 05432/0203291-US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Ask Puschl et al.

Application No.: 10/551,883 Confirmation Number: 6788

Filed: November 29, 2005 Art Unit: 1614

For: 4-(2-PHENYLSULFANYL-PHENYL)- Examiner: Not Yet Assigned

PIPERIDINE DERIVATES AS SEROTONIN

REUPTAKE INHIBITORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

- []A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [x] B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- [] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

Counsel states that, upon information and belief, each item of [] i. information listed herein was (check one of boxes (a) or (b)) [] (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS. A check for the fee set forth in 1. 17(p), presently believed to be [] ii. \$180, is enclosed. after (A), (B) and (C) above, but before payment of the issue fee: [] D. Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 CFR 1.17(i) a check in the amount of \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b)) [] (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or [] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS. 2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below. (check boxes A, B and/or C and fill in blanks, if appropriate.) Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted. [] B. Document(s) is (are) deemed substantially cumulative to document(s) _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed. Certain documents were previously cited by or submitted to the [] C. Office in the following prior applications, which are relied upon

under 35 U.S.C. 120:

[SERIAL NO. & FILING DATE].

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application. [] 3. Cite Nos. _____ are not in the English language. In accordance with 1.98(c), Applicant states: An English translation of each document (or of the pertinent []portions thereof), or a copy of each corresponding Englishlanguage patent or application, or English-language abstract (or claim) is enclosed. The requirement for a concise explanation of the relevance of any \prod foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609). A concise explanation of the relevance of document(s) []is set forth as follows: [Insert concise explanation of relevancel A concise explanation of the relevance of document(s) can be found on page(s) _____ of the specification. A concise explanation of document(s) ____ can be found on the []attached sheet. [] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20). [] 5. Other information being provided for the examiner's consideration follows: [A/An _____, which issued during the prosecution of _____ Application No. ____ which corresponds to the present application.] 6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the

date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

CROSS REFERENCE UNDER 37 C.F.R. §1.78 TO RELATED APPLICATIONS

	Pursuant	to 37	C.F.R.	(§1.78,	Applicant	notes	that	the	above-identified	patent
applio	cation may	be rela	ated to tl	ne follow	ving U.S. P	atent A	Appli	catic	ons:	

(1) U.S. Provisional Application Serial No ______, filed _____.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

May 5, 2006

S Peter Ludwig

Registration No. 25,351 Attorney for Applicant(s)

DARBY & DARBY P.C. P.O. Box 5257 New York, N.Y. 10150-5257 (212) 527-7700



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete if Known				
Application Number	10/551,883-Conf. #6788			
Filing Date	November 29, 2005			
First Named Inventor	Ask Puschl			
Art Unit	1614			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	05432/0203291-US0			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

1

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,				
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear				
	ВА	WO-2005/000309-A2 & A3	01-06-2005	IONIX Pharmaceuticals		1			
	1			Limited					
	BB	WO-2004/085385-A2 & A3	10-07-2004	Schering Corporation		\neg			
	ВС	WO-01/10842-A2 & A3	02-15-2001	Millennium Pharmaceuticals,		\overline{A}			
i	1			Inc.					
	BD	WO-02/062766-A2 & A3	08-15-2002	Millennium Pharmaceuticals,		\overline{A}			
	ł			Inc.					
	BE	WO-00/59878-A2& A3	10-12-2000	ICOS Corporation		abla			
	BF	WO-99/17777	04-15-1999	Merck & CO., INC.					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date Signature Considered			
Signature Considered	Examiner	Date	
	Signature	Considere	ed

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



Application No. (if known): 10/551,883

Attorney Docket No.: 05432/0203291-US0

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 770096101 US in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	May 8, 2006	·
	Date	
	D	
	,	Signature
		Donna M. Tirella
	Typed or printe	ed name of person signing Certificate
		212.527.7700
Regis	tration Number, if applicable	Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement (4 pages) PTO SB/08 (1 page)

Coies of 6 doucments cited Return Receipt Postcard